122 filings
Page 3 of 7
8-K
2xin186d2c9spbyl7e
27 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:00am
8-K
cydh6oe
2 Mar 23
Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from
9:00am
424B1
bzuu9wkqt6ykke a8n
10 Feb 23
Prospectus with pricing info
4:11pm
EFFECT
3d3 nn8ccu
9 Feb 23
Notice of effectiveness
12:15am
CORRESP
zifsq 5ap
6 Feb 23
Correspondence with SEC
12:00am
UPLOAD
afoycx nt9
3 Feb 23
Letter from SEC
12:00am
8-K
99ltv 29hk0zuc4t
9 Jan 23
Vivos Therapeutics Announces Pricing of $8 Million Private Placement
7:30am
8-K
9p9vvgqy
20 Dec 22
Vivos Therapeutics Reports Second and Third Quarter 2022 Financial Results and Provides Operational Update
4:15pm
8-K
yyal4t5ksvc83uprv9
29 Nov 22
Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q
8:00am
8-K
e6ow0 0a3ls8c5ob
22 Nov 22
Vivos Therapeutics Provides Update on Revenue Recognition Review
7:45am
8-K
5jw51irt
4 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
vxci rixv9nxbv
26 Aug 22
Submission of Matters to a Vote of Security Holders
4:05pm
NT 10-Q
jqntv2187o05pwa ez
15 Aug 22
Notice of late quarterly filing
4:38pm
8-K
1nztq6gheh25b
15 Jul 22
Vivos Therapeutics Announces Multiple Regulatory Clearances in Australia for its Entire Line of Oral Appliances
10:00pm
8-K
wxd7scumv5qn q5
14 Jun 22
Vivos Therapeutics’ SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea
8:54pm